According to Zhitong Finance App News, Sinopharm (000028.SZ) released a performance report for the first three quarters of 2026. From January to September 2026, the company achieved operating income of 55.066 billion yuan, down 0.11% year on year; net profit attributable to shareholders of listed companies was 952 million yuan, down 0.48% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 945 million yuan, up 2.36% year on year.
From January to September 2026, the distribution sector achieved operating income of 40.565 billion yuan, a year-on-year decrease of 0.07%; net profit of 754 million yuan, an increase of 4.28% year-on-year. Despite being influenced by the continued deepening of industry policies, the company insisted on consolidating its core business, actively expanding the market and adjusting the business structure. The revenue decline continued to narrow, and profit growth regained its upward trend, showing good management resilience. The retail sector (“Sinopharm Holdings Guoda Pharmacy Co., Ltd.”, “Guoda Pharmacy” for short) achieved operating income of 15.234 billion yuan, an increase of 0.05% over the previous year; realized net profit of 0.27 billion yuan, an increase of 105.08% over the previous year. National University Pharmacy's sales revenue has gradually stabilized. Through continuous optimization of the product structure and strategic adjustment of the store layout, cost control has been further strengthened, and the quality of operations has been improved. During the reporting period, the net profit of National University Pharmacies achieved year-on-year growth.